GameStop's sinking share price is sending WallStreetBets Redditors ballistic
Reddit favorite GameStop isn't looking so hot this week and some of the stock's biggest backers are freakin...
Stay updated with breaking news from Markets Now. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Reddit favorite GameStop isn't looking so hot this week and some of the stock's biggest backers are freakin...
‘Stop f—ing selling!!!’ WallStreetBets Redditors go ballistic over GameStop’s sinking share price Reddit favorite GameStop isn’t looking so hot this week and some of the stock’s biggest backers are freaking out. After selling off sharply all week, the stock fell another 42% Thursday. “We have the advantage. All we have to [do] is buy and hold shares,” wrote one of the users. Robinhood briefly placed restrictions on trades in GameStop last week. Both Citadel the hedge fund and Citadel Securities have both denied any role in this decision. Elsewhere on the forum, another said: â...
U.S. stocks are rallying to records Wednesday on encouraging earnings reports and continued optimism that new leadership in Washington will mean more support for the struggling economy.
By Barbara Kollmeyer Order Reprints Text size A general view of a Total petrol station in Kampala, Uganda, on Jan. 28, 2020. AFP via Getty Images They say it’s lonely at the top. For France’s Total, years of dominance on the oil patch are over, say analysts at Cowen, who downgraded the company to market perform from outperform in a note to clients on Tuesday. Jason Gabelman and George Kuhle say they continue to like Total’s strategy, but it faces a tougher two years ahead. “TOT is trading at an elevated premium versus peers while we expect it...
The fate of two experimental drugs to treat early stage Alzheimer’s sent shares of Biogen on a wild ride this week. Analysts at Truist raised their price target on Lilly (ticker: LLY) to $200 from $182 after the company revealed optimistic results from a stage 2 trial of its donanemab treatment, which was found to slow the decline in cognition and function in Alzheimer’s patients. The new price target implies an 11% gain from the current price. Lilly shares jumped on Monday after the news, but settled back on Tuesday, falling 3.2%. It is up 6.9% this year compared to a 1.3% gain ...